NASDAQ$LFCR

Lifecore Biomedical Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Reported third quarter and first nine months fiscal 2020 results.

Landec Corporation reported a decrease in revenues and gross profit for the third quarter of fiscal 2020, with revenues at $152.9 million and gross profit at $20.0 million. The company experienced a net loss of $11.5 million, which includes $12.7 million of restructuring and other non-recurring charges, net of tax. Adjusted EBITDA was $6.8 million, excluding $16.8 million of restructuring and other non-recurring charges.

  • Revenues of $152.9 million, a decrease of 2% year over year
  • Gross profit of $20.0 million, a decrease of 7% year over year
  • Net loss of $11.5 million, which includes $12.7 million of restructuring and other non-recurring charges, net of tax.
  • Adjusted EBITDA was $6.8 million, which excludes $16.8 million of restructuring and other non-recurring charges

Headline financials

Total Revenue

$153M

Previous: $156M-1.8%
EPS (adj)

$0.04

Previous: $0.04+0.0%
Capital Expenditures

-$22.1M

Previous: -$33.1M+33.3%
Free Cash Flow

-$33.6M

Previous: -$32.1M-4.9%
Net Income

-$11.5M

Previous: $1.07M-1179.5%
Operating Income

-$15M

Previous: $2.63M-670.1%
Gross Profit

$20M

Previous: $21.2M-5.5%
Cash & Equivalents

$2.61M

Previous: $1.72M+51.4%
Total Assets

$550M

Previous: $502M+9.7%
Stock-Based Comp

$566K

Previous: $816K-30.6%

Revenue & EPS history

Lifecore Biomedical · Revenue · Quarterly

$153M

Q3 2020-1.8%vs Q3 2019
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Lifecore Biomedical · $24.3M total across 1 segment · Q4 2023

  • CDMO Revenue
    $24.3M

Forward guidance

Excluding restructuring and other nonrecurring charges, tax implications and any potential impact of the COVID-19 pandemic, the Company is reiterating its full year fiscal 2020 guidance

Tailwinds

  • Consolidated Revenues: range of $580 million to $590 million (growth of 4% to 6%)
  • Lifecore: range $84 million to $85 million (growth of 10% to 12%)
  • Curation Foods: range of $496 million to $504 million (growth of 3% to 5%)
  • Consolidated Adjusted EBITDA: range $30 million to $34 million (growth of 15% to 30%)
  • Lifecore Adjusted EBITDA: range of $21 million to $23 million (growth of 5% to 15%)

Headwinds

  • Curation Foods Adjusted EBITDA: range of $12 million to $14 million (growth of 70% to 90%)
  • Consolidated Adjusted diluted net income per share: range of $0.16 to $0.20

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

-2.1%

Avg return

Earnings day

-2.7%

Avg return

5 days after

-0.4%

Avg return

30 days after

40%

25 / 63 earnings

Positive

+19.5%

Q2 2013

Best reaction

-66.7%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-3.9%-13.0%+8.9%
Q1 2026-0.1%+7.5%+12.5%
Q4 2025-6.3%-0.3%-3.0%
Q3 2025-22.3%-8.5%+7.0%
Q1 2025+8.1%-3.6%+24.8%
Q4 2024-21.0%-27.0%-21.0%
Q3 2024+8.2%+15.7%-5.0%
Q2 2024+8.2%+15.7%-5.0%
Q1 2024+8.2%+15.7%-5.0%
Q4 2023-13.2%-13.7%-16.8%
Q3 2023-0.5%+3.8%+18.1%
Q2 2023-66.7%-35.1%-23.6%
Q1 2023-5.3%-5.4%+4.0%
Q4 2022+4.7%+7.1%-6.0%
Q3 2022-8.3%-9.6%-20.8%
Q2 2022-1.8%-8.1%-2.5%
Q1 2022-9.6%-10.4%-4.7%
Q4 2021-6.8%-12.4%-10.5%
Q3 2021-10.4%-10.0%+12.0%
Q2 2021-2.2%-0.9%-0.8%
Q1 2021+1.2%+0.8%-2.7%
Q4 2020-14.4%-9.0%-9.4%
Q3 2020+15.3%+15.6%+31.6%
Q2 2020-11.3%-10.5%-1.0%
Q1 2020-3.6%-6.1%-9.4%
Q4 2019+5.2%-1.1%+3.7%
Q3 2019-9.3%-17.5%-18.7%
Q2 2019-12.4%-3.6%+8.1%
Q1 2019-0.2%-4.1%-2.5%
Q4 2018-5.7%-5.3%-5.3%
Q3 2018+6.5%+3.4%+1.9%
Q2 2018+3.2%+3.2%+4.8%
Q1 2018+11.3%+8.4%+9.6%
Q4 2017-7.7%-9.4%-8.7%
Q3 2017+10.1%+19.7%+16.0%
Q2 2017-2.5%-2.2%-10.9%
Q1 2017+5.6%+5.3%+4.4%
Q4 2016+2.1%+1.1%+10.9%
Q3 2016+0.5%
Q2 2016-0.1%
Q1 2016-4.0%
Q4 2015-1.3%
Q3 2015+1.2%
Q2 2015-1.5%
Q1 2015-2.0%
Q4 2014+5.0%
Q3 2014-2.7%
Q2 2014+1.1%
Q1 2014-8.4%
Q4 2013-2.7%
Q3 2013+4.0%
Q2 2013+19.5%
Q4 2010-1.7%
Q1 2013-0.3%
Q4 2012+0.9%
Q3 2011-0.5%
Q3 2012-0.5%
Q2 2011-0.5%
Q2 2012-0.5%
Q1 2011+1.5%
Q1 2012+1.5%
Q4 2011+1.5%
Q3 2010+5.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro